151. Design, synthesis and in vitro activities on anti-platelet aggregation of 4-methoxybenzene-1,3-isophthalamides.
- Author
-
Liu XJ, Shi XX, Zhong YL, Liu N, and Liu K
- Subjects
- Animals, Dose-Response Relationship, Drug, Drug Delivery Systems, Inhibitory Concentration 50, Magnetic Resonance Spectroscopy, Phthalic Acids chemistry, Phthalic Acids pharmacology, Phthalimides chemistry, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors chemistry, Rats, Blood Platelets drug effects, Drug Design, Phthalimides chemical synthesis, Phthalimides pharmacology, Platelet Aggregation Inhibitors chemical synthesis, Platelet Aggregation Inhibitors pharmacology
- Abstract
On the purpose of searching for the structure-activity relationship (SAR) and obtaining novel anti-platelet drugs, 41 4-methoxybenzene-1,3-isophthalamides have been described the synthesis process and in vitro activities on anti-platelet aggregation. The target compounds have been classified into four series: series 1 (ortho-substituted phenyl: 1a-1j), series 2 (meta-substituted phenyl: 2a-2k), series 3 (para-substituted phenyl: 3a-3l) and series 4 (aromatic of no substituted group and aromatic heterocyclic substituted groups: 4a-4h). The chemical structures of the target compounds were confirmed by MS, IR, (1)H NMR, and their in vitro activities on anti-platelet aggregation were tested and assessed by using Born test. The result showed that thirteen compounds 1c, 1d, 1i, 1j, 2g, 3a, 3c, 3d, 3f, 3h, 3l, 4b and 4c have superior anti-platelet aggregation activities than the reference drug Picotamide., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF